1. Scrip
  2. >>Therapy Areas

CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients

Data for JCAR017 in diffuse large B-cell lymphoma to be presented at the upcoming ASH meeting suggest that the therapy has best-in-class safety and efficacy, paving the way for use outside major medical centers, a potential competitive advantage.

3d illustration of T cells or cancer cells

Juno Therapeutics Inc. is highlighting the potential of its CAR T-cell therapy JCAR017 to be used in earlier lines of therapy and perhaps in the outpatient setting, based on the strong safety and efficacy profile demonstrated in updated diffuse large B-cell lymphoma data from the Phase I TRANSCEND study.

JCAR017 is a CD19-directed, autologous chimeric antigen receptor T-cell (CAR-T) product that

More from Immuno-oncology

More from Anticancer